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Abstract
Caveolin-1, the structural protein component of caveolae, acts as a scaffolding protein that functionally regulates signaling
molecules. We show that knockdown of caveolin-1 protein expression enhances chemotherapeutic drug-induced apoptosis
and inhibits long-term survival of colon cancer cells. In vitro studies demonstrate that caveolin-1 is a novel Ku70-binding
protein, as shown by the binding of the scaffolding domain of caveolin-1 (amino acids 82–101) to the caveolin-binding
domain (CBD) of Ku70 (amino acids 471–478). Cell culture data show that caveolin-1 binds Ku70 after treatment with
chemotherapeutic drugs. Mechanistically, we found that binding of caveolin-1 to Ku70 inhibits the chemotherapeutic drug-
induced release of Bax from Ku70, activation of Bax, translocation of Bax to mitochondria and apoptosis. Potentiation of
apoptosis by knockdown of caveolin-1 protein expression is greatly reduced in the absence of Bax expression. Finally, we
found that overexpression of wild type Ku70, but not a mutant form of Ku70 that cannot bind to caveolin-1 (Ku70 WRA),
limits the chemotherapeutic drug-induced Ku70/Bax dissociation and apoptosis. Thus, caveolin-1 acts as an anti-apoptotic
protein in colon cancer cells by binding to Ku70 and inhibiting Bax-dependent cell death.
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Introduction
Caveolae are 50 to 100 nm flask-shaped invaginations of the
plasma membrane enriched in cholesterol and glycosphingolipids.
Caveolae can exist as individual invaginations or are found in
detached grape-like clusters and long tubular structures derived
from the fusion of single caveolae within the cytoplasm. Caveolae
were identified in the 1950’s in capillary endothelial cells and
epithelial cells from the gall bladder of the mouse [1,2]. Since then,
caveolae have been found in a wide variety of tissues and cell
types, including adipocytes, endothelial cells, striated and smooth
muscle cells, fibroblasts and epithelial cells [3]. Caveolae were
originally thought to function as macromolecular transport vesicles
[4]. From then on, their role has expanded to signal transduction,
cellular metabolism, cholesterol homeostasis, endocytosis and
tumor suppression [5–9].
Caveolin-1 is an essential protein component of caveolae.
Caveolin-1 acts as a scaffolding protein that concentrates and
functionally regulates signaling molecules, including G-protein
alpha subunits, H-Ras, Nitric Oxide Synthase (NOS), Epidermal
Growth Factor Receptor (EGFR), Src-like Nonreceptor Tyrosine
Kinases (NRTK), Protein Kinase C (PKC), Protein Kinase A
(PKA), Mdm2, Thioredoxin Reductase 1 and Protein Phosphatase
type 2A [10–13]. The direct interaction between caveolin-1 and
signalling molecules occurs between the ‘‘caveolin scaffolding
domain’’ (CSD) of caveolin-1, which is represented by residues
82–101, and the caveolin binding domain (CBD: WXWXXXXW,
WXXXXWXXW, or WXWXXXXWXXW where W represents an
aromatic amino acid and X represents any amino acid) of
signaling molecules [14,15]. The direct interaction with caveolin-1
generally results in the sequestration of a given signaling molecule
within caveolar membranes and inhibition of its signaling activity.
Colorectal cancer is the fourth most commonly diagnosed
cancer and the second leading cause of cancer-related deaths in
the United States [16,17]. Apoptosis is an anti-tumorigenic event.
In fact, tumor cells need to escape apoptosis in order to generate a
relevant tumor mass. Thus, apoptosis has a profound effect on the
malignant phenotype. In addition, most cytotoxic anticancer
agents promote apoptosis, suggesting that defective apoptotic
programs may contribute to treatment failure, which is commonly
seen in most human cancers. Studies have shown that caveolin-1 is
over-expressed in colon cancer tissues, as compared to normal
colonic mucosa, and colon cancer cells [18–20], suggesting that
caveolin-1 may have pro-tumorigenic properties in this type of
cancer. However, whether and how caveolin-1 modulates
apoptosis of colon cancer cells remains to be determined.
An important regulatory step in apoptosis is the activation of the
proapoptotic factor Bax, which translocates to the outer
mitochondrial membrane and oligomerizes following its activa-
tion. Bax promotes apoptosis by making the membrane permeable
to cytochrome c. Ku70 is a protein that was originally identified as
part of the Ku70/Ku80 complex that mediates the repair of DNA
double-strand breaks by non-homologous end joining (NHEJ)
[21]. However, Ku70 has also been shown to regulate apoptosis
through a Bax-dependent mechanism. Over-expression of Ku70
inhibits Bax-mediated apoptosis, whereas depletion of Ku70
enhances apoptosis [22]. In addition, Ku70 2/2 mice are
hypersensitive to ionizing radiation [23] and cells from these mice
are also hypersensitive to apoptosis induced by staurosporine [24].
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Increased acetylation of Ku70 disrupts the Ku70-Bax interaction
and inhibits the antiapoptotic function of Ku70 [25]. Finally,
peptides based on the amino acid sequence of the Bax-binding
domain of Ku70 bind Bax and inhibit cell death [26,27]. Thus, by
interacting with Ku70, Bax is sequestered away from mitochon-
dria and is maintained in an inactive state. The molecular
mechanism underlying the sequestration of Bax by Ku70 and the
release of Bax from Ku70 after stimulation with an apoptotic
inducer remains to be fully identified.
In this study, we focused on the functional role of caveolin-1 in
chemotherapeutic-induced apoptosis of colon cancer cells and the
underlying molecular mechanism. We found that Ku70 is a novel
caveolin-1-binding protein and that binding of caveolin-1 to Ku70
inhibits chemotherapeutic drug-induced apoptosis of colon cancer
cells by limiting the release of Bax from Ku70.
Materials and Methods
Materials
Antibodies and their sources were as follows: anti-caveolin-1
(2297) and anti-Bax (6A7) IgGs were from BD Transduction
Laboratories (Lexington, KY); anti-caveolin-1 (H-97), anti-Ku70
(A-9) and anti-Bax (N-20) IgGs were from Santa Cruz Biotech-
nology (Santa Cruz, CA); anti-cleaved caspase-3 and anti-cleaved
PARP IgGs were from Cell Signaling Technology (Danvers, MA);
horseradish peroxidase-conjugated goat anti-mouse and anti-
rabbit secondary antibodies were from Pierce (Rockford, IL,
USA). McCoy’s 5a medium and fetal bovine serum were
purchased from Invitrogen (Carlsbad, CA). Other biochemicals
used were of the highest purity available and were obtained from
regular commercial sources.
Cell Culture and Drug Treatment
Human colon carcinoma cells HT29, HCT116 Bax +/2
(HCT116) and HCT116 Bax 2/2 (HCT116 Bax null) (a
generous gift from Dr. Bert Vogelstein) were grown in McCoy’s
5a medium containing glutamine, antibiotics and 10% FBS. Cells
were incubated in growth medium supplemented with 50, 25,
12.5, 6.25, or 3.125 mg/ml of 5-FU for 12, 24 or 48 hours.
HCT116 and HCT116 Bax null cells were also incubated in
growth medium supplemented with 800, 600, 400 or 200 mM of
etoposide for 24 hours.
siRNA Treatment
Knockdown of caveolin-1 protein expression was achieved by
transfection of HCT116 and HT29 cells with small interfering
RNA (siRNA) duplexes. The target sequence was as follows: 59-
aaccagaagggacacacag-39. Scrambled siRNA was used as a
negative control. Transfection was performed using Lipofectamine
2000 according to the manufacture’s recommendations.
Cloning of wild type (WT) and WRA Ku70
constructs. The entire coding region of mouse Ku70 was
amplified by polymerase chain reaction amplification using a full-
length cDNA clone (ID 3669715) from Open Biosystems
(Huntsville, AL) and the following primers: forward 59-gaattcggt-
cagagtgggagtcctactac-39 and reverse 59-ctcgagtcagttcttctccaagtgtct-
39. The amplified DNA was sequenced to rule out the introduction
of unwanted mutations. The PCR fragment was digested to create
unique EcoRI and XhoI ends and subcloned into the pCMV-HA
expression vector (WT Ku70-HA). The WRA mutant of Ku70
(WRA Ku70-HA) was generated by replacement of the aromatic
residues within the caveolin binding motif of Ku70 (amino acids
471–478) with alanines by polymerase chain reaction amplifica-
tion using appropriate internal primers (forward: 59-
gttcaaaagctccgcgccacagccagatctgacagtgctgagaatccagtcctg-39; re-
verse: 59-caggactggattctcagcactgtcagatctggctgtggcgcggagcttttgaac-
39) and subcloned EcoRI and XhoI into the pCMV-HA
expression vector. Transfection of WT Ku70-HA and WRA
Ku70-HA in HCT116 cells was performed using Lipofectamine
2000 according to the manufacture’s recommendations.
Western Blotting Assay
Protein samples were collected in boiling Laemmli buffer (0.2 M
Tris-HCl, pH 6.8, 2% SDS, 10% glycerol), vigorously resus-
pended and boiled for 5 min. Protein concentration was calculated
using the BCA protein assay kit (Thermo Fisher Scientific Inc.,
Rockford, IL). Equal amount of proteins were separated on 12.5%
Tris-HCl polyacrylamide gels after the addition of 0.01%
bromophenol blue and 20 mM DTT. Protein samples were then
transferred onto nitrocellulose membranes overnight at 4uC.
Ponceau S staining was performed to confirm equal loading.
Blots were incubated for 1 hr in TBST (10 mM Tris-HCl, pH 8.0,
150 mM NaCl, and 0.2% Tween 20) containing 2% dry milk and
1% bovine serum albumin. After three washes with TBST,
membranes were incubated overnight with the primary antibody
and for 1 hr with horseradish peroxidase-conjugated secondary
IgG. Bound antibodies were detected using a Super Signal
chemiluminescent solution (Pierce Chemical, Rockford, IL).
DAPI (4,6-Diamidino-2-Phenylindole) Staining
HCT116 and HT29 cells (untreated or treated with chemo-
therapeutic drugs) were harvested and incubated with staining
buffer (PBS containing 3.7% paraformaldehyde, 0.1% Triton,
10 mg/ml RNase A and 1 mg/ml DAPI) at room temperature for
1 hr. Nuclear morphology was examined under a Olympus Provis
fluorescent microscope. A total of 1,200 cells were scored from 4
independent viewing areas from three independent experiments
for each experimental point.
Annexin V staining and flow cytometry
analysis. HCT116 cells were transfected with caveolin-1 siRNA
and scrambled siRNA as described above. After 24 hours, cells
were treated with 25 mg/ml 5-FU for 48 hours. Untreated cells
were used as control. The Annexin-V-FITC Apoptosis Detection
Kit (BD Pharmingen, San Diego, CA) was used to detect apoptosis
by flow cytometry. Cells were harvested (including detached cells),
and processed according to the manufacturer’s instructions.
Fluorescence-activated cell sorting analysis was carried out using
a FACScan flow cytometer (Becton Dickinson, San Diego, CA)
and CellQuest software.
Clonogenic Assay
HCT116 cells were transfected with either caveolin-1 siRNA or
scrambled siRNA as described above. After 24 hours, cells were
treated with different concentrations of either 5-FU (3.125 mg/ml,
6.25 mg/ml, 12.5 mg/ml and 25 mg/ml) or etoposide (200 mM,
400 mM and 600 mM) for 1 hour. Untreated cells were used as
control. 500 cells were then plated into 12-well plates and cultured
for 7 days. Cells were stained with crystal violet by incubating the
cells with 10% crystal violet in 70% ethanol for 2 minutes followed
by extensive washes with PBS. Quantification of crystal violet
staining from three independent experiments was performed by
counting the number of clones using Image J software analysis.
Cell Cycle Analysis by Fluorescence-activated Cell Sorter
(FACS)
Cells were collected by trypsinization, pelleted, and washed with
PBS. Cells were resuspended and fixed overnight with 1 ml of ice-
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cold 70% ethanol at 4uC. On the day of analysis, cells were
centrifuged at 3000 rpm for 8 min and the supernatant was
carefully removed. Subsequently, cells were resuspended in 1.0 ml
of PI solution (PBS containing 0.1% glucose, 1.1 mg/ml RNAse,
and 0.05 mg/ml propidium iodide) and incubated at room
temperature for 30 min. Cell were then subjected to FACS
analysis with the use of a flow cytometer (LSR II, BD biosciences).
For each analysis 10,000 gated events were collected to permit cell
cycle analysis. Data analysis was performed with the use of
CellQuest software. A representative cell cycle analysis from three
independent experiments is shown.
Glutathione S-transferase (GST) Pull-down Assay
GST-caveolin-1 (GST-Cav-1) constructs were as follows: GST
fused to full-length caveolin-1 (Cav-1 FL), GST fused to residues
82 to 101 of caveolin-1 (GST-Cav-1 (82–101)) and GST fused to
residues 1 to 101 of caveolin-1 (GST-Cav-1 (1–101)). GST-Cav-1
fusion protein constructs were transformed into Escherichia coli
(BL21 strain; Novagen, Inc.). After induction of expression
through addition of 0.5 mM isopropyl-b-D-galactoside (Sigma),
GST-Cav-1 proteins were affinity purified on glutathione-agarose
beads, using the detergent Sarcosyl for initial solubilization. GST-
Cav-1 and GST alone (bound to glutathione-agarose beads) were
washed 3 times with TNET buffer (50 mM Tris, pH 8.0, 150 mM
NaCl, 5 mM EDTA, 1% Triton X-100) containing protease
inhibitors. SDS-PAGE followed by Comassie staining was used to
determine the concentration of GST-Cav-1 per 100 ml of packed
bead volume. Pre-cleared cell lysates of HCT116 cells over-
expressing HA-Ku70 were diluted in buffer A (10 mM Tris,
pH 8.0, 0.1% Tween 20) and added to approximately 100 ml of
equalized bead volume for overnight incubation at 4uC. After
binding, the beads were extensively washed with phosphate-
buffered saline (6 times). Finally, the beads were resuspended in
2X sample buffer (0.4 M Tris-HCl, pH 6.8, 4% SDS, 20%
glycerol, 0.02% bromophenol blue) and subjected to SDS-PAGE.
Co-Immunoprecipitation
Cellswerewashed twicewithPBSand lysed for45 minat4uCinan
IP lysis buffer (10 mMTris, pH 8.0, 150 mMNaCl, 5 mMEDTA,
1% Triton X-100, 60 mM octyl glucoside and protease inhibitors;
Bax immunoprecipitation was performed using 0.1 mMHepes and
1%CHAPS). Subsequently, lysateswerecentrifugedat13,0006g for
10 min at 4uC. The supernatant was pre-incubated with protein A
sepharose beads for 1 hr at 4uC. After centrifugation at 10,000 rpm
for 30 sec, the supernatant was collected and protein concentration
calculated using the BCAprotein assay kit (Thermo Fisher Scientific
Inc.).Equal amountof total proteinswere incubatedovernight at4uC
with anti-caveolin-1 or anti-Bax antibodies and protein A sepharose
beads. The immunoprecipitates were washed three times with lysis
bufferandre-suspendedinLaemmlibuffer (0.2 MTris-HCl,pH 6.8,
2% SDS, 10% glycerol, 0.01% bromophenol blue, 20 mM DTT).
Following vigorous vortexingandboiling, sampleswere separatedon
12.5% SDS-PAGE. Blots were then probed with appropriated
antibodies. Immunoprecipitations with protein A sepharose beads
were performed as control and did not produce any detectable band
by immunoblotting analysis using the appropriate antibody (data not
shown).
Mitochondria Isolation
Cells were washed once in PBS and resuspended in 600 mL of
mitochondrial isolation buffer containing 10 mM Hepes (pH 7.4),
250 mM sucrose, 1 mM EDTA and protease inhibitors. Cells
were broken in a Dounce homogenizer for 40 times. Nuclei and
unbroken cells were removed by centrifugation at 10006g at 4uC
for 15 min. Clarified lysates were subjected to centrifugation at
12,0006g at 4uC for 15 min. The mitochondrion-containing
pellets were resuspended in 2x SDS sample buffer. Mitochondrial
fractions were positive for the mitochondria marker cytochrome
oxidase subunit IV and negative for the cytoplasmic marker alpha-
tubulin (data not shown).
RNA Isolation and RT-PCR
Cells were collected and total RNAwas isolated using theRNeasy
Mini kit from Qiagen (Valencia, CA). Equal amounts of RNA were
treated with RNase-free DNase, and subjected to reverse transcrip-
tion using theAdvantageRT-for-PCR kit fromClontech (Mountain
View, CA), according to the manufacturer’s recommendations.
PCR was then performed in the exponential linear zone of
amplification for each gene studied. The caveolin-1-specific primers
used were the following: forward 59-ctacaagcccaacaacaagg-39;
reverse 59- cagacagcaagcggtaaaa-39. A sequence corresponding to
GAPDH was also amplified as an internal control.
Immunofluorescence Microscopy
Cells grown on glass coverslips were washed three times with
PBS w/Ca++/Mg++ and fixed for 30 min at room temperature
with 2% paraformaldehyde in PBS w/Ca++/Mg++. Fixed cells
were rinsed with PBS w/Ca++/Mg++and permeabilized with 0.1%
Triton X-100, 0.2% bovine serum albumin for 10 min. Then cells
were treated with 25 mM NH4Cl in PBS w/Ca
++/Mg++ for
10 min at room temperature to quench free aldehyde groups.
Cells were treated with RNase (200 mg/ml) for 10 minutes and
with DAPI (1 mg/ml) for 20 minutes. Cells were rinsed with PBS
w/Ca++/Mg++ and incubated with the primary antibody (diluted
in PBS with 0.1% Triton X-100, 0.2% bovine serum albumin) for
2 h at room temperature. After three washes with PBS w/Ca++/
Mg++ (10 min each), cells were incubated with the secondary
antibody for 1 h at room temperature: lissamine rhodamine B
sulfonyl chloride-conjugated goat anti-rabbit antibody (5 mg/ml)
and fluorescein isothiocyanate-conjugated goat anti-mouse anti-
body (5 mg/ ml). Finally, cells were washed three times with PBS
w/Ca++/Mg++ (10 min each wash) and slides were mounted with
slow-Fade anti-fade reagent (Molecular Probes, Inc., Eugene, OR)
and observed using a Zeiss Confocal Microscope (LSM 5 Pascal).
Statistical Analysis
Quantification studies were performed in triplicate and the
average 6 standard error of the mean (S.E.M.) is shown.
Significance was calculated using the Student’s t-test. Quantifica-
tion of active Bax was obtained by scanning images of western
blotting analysis from three independent experiments using Image
J software. Immunoprecipitation and immunoblotting analysis
were performed three independent times and representative blots
are shown.
Results
Caveolin-1 Inhibits Chemotherapeutic Drug-induced
Apoptosis and Promotes Long-term Survival of Colon
Cancer Cells
To directly address the role of caveolin-1 in chemotherapeutic
drug-induced apoptosis in colon cancer cells, we knocked-down
caveolin-1 protein expression by siRNA in HCT116 colon cancer
cells (Figure 1A). Scrambled and caveolin-1 siRNA-transfected
HCT116 cells were treated with different concentrations
(3.125 mg/ml, 6.25 mg/ml, 12.5 mg/ml and 25 mg/ml) of the
chemotherapeutic drug 5-fluoracil (5-FU) for 48 hours (Figure 1B)
Caveolin-1, a Novel Ku70-Interacting Protein
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and with the same concentration of 5-FU (25 mg/ml) for different
periods of time (12 h, 24 h and 48 h) (Figures S1A and S1B). Cells
were then stained with DAPI and apoptosis was quantified by
counting the number of cells showing nuclear condensation. We
show that 5-FU induced apoptosis in HCT116 cells transfected
with scrambled siRNA and that 5-FU-induced apoptosis was
significantly enhanced in HCT116 cells in which caveolin-1
protein expression was reduced by siRNA. These data were
confirmed by annexin V staining followed by flow cytometry
analysis (Figure 1C) and immunoblotting analysis using antibody
probes specific for cleaved caspase 3 and Poly (ADP-ribose)
polymerase (PARP) (Figure 1D). Studies have implicated reactive
oxygen species (ROS) in 5-FU-mediated apoptosis in colon cancer
cells [28]. To independently support our findings, we subjected
HCT116 cells transfected with either scrambled or caveolin-1
siRNA to oxidative stress and apoptosis was quantified by DAPI
staining. We found that knockdown of caveolin-1 protein
expression potentiated oxidative stress-induced apoptosis in
HCT116 cells (data not shown).
Long-term clonogenic assays provide a more stringent mea-
surement of cell survival than short-term assays. To determine the
effect of reduced caveolin-1 expression on the long-term survival of
colon cancer cells, HCT116 cells were transfected with either
scrambled or caveolin-1 siRNA, treated with different concentra-
tions of 5-FU (3.125 mg/ml, 6.25 mg/ml, 12.5 mg/ml and 25 mg/
ml) and subjected to crystal violet staining 7 days after 5-FU
treatment. Figures 2A and 2B show that knockdown of caveolin-1
protein expression reduced the long-term survival of HCT116
cells, even at the lowest concentration of 5-FU (3.125 mg/ml).
Interestingly, the number of clones, after crystal violet staining,
was reduced by the knockdown of caveolin-1 protein expression in
HCT116 cells even before drug treatment (Figure 2A). Since
caveolin-1 siRNA also reduced the number of cells in the S phase
of the cell cycle by 13%, without promoting apoptosis, before
treatment with 5-FU (Figure S2), caveolin-1 appears to have a
positive effect on cell growth in HCT116 cells in addition to its
anti-apoptotic function after stimulation with chemotherapeutic
drugs. This is consistent with data showing pro-tumorigenic
properties of caveolin-1 in colon cancer, as demonstrated by the
Figure 1. Knockdown of caveolin-1 protein expression sensitizes HCT116 colon cancer cells to apoptosis. HCT116 colon cancer cells
were transfected with siRNA directed against caveolin-1. Transfection with scrambled siRNA was used as control. (A) Endogenous caveolin-1
expression was determined by immunoblotting analysis 24, 48 and 96 hours after transfection using an antibody probe specific for caveolin-1.
Immunoblotting with anti-b-actin IgGs was done to show equal loading. (B–D) One day after transfection, HCT116 cells were treated with different
concentrations of 5-FU for 48 hours. Untreated cells were used as control. In (B), cells were stained with DAPI and the number of cells showing
nuclear condensation was quantified. Values represent mean6 SEM; *P,0.001; #P,0.005. In (C), cells were subjected to Annexin V staining and flow
cytometry. Values represent mean. In (D), cells were subjected to immunoblotting analysis with antibody probes specific for cleaved caspase 3 and
PARP. Immunoblotting with anti-b-actin IgGs was done to show equal loading.
doi:10.1371/journal.pone.0039379.g001
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over-expression of caveolin-1 in colon cancer tissues and colon
cancer cells [18–20].
To determine whether the caveolin-1-mediated inhibition of
apoptosis is not limited to the combination of HCT116 cells and 5-
FU, a different colon cancer cell line, HT29, was treated with
different concentrations of 5-FU after caveolin-1 protein expres-
sion was knockdown by siRNA (data not shown). Apoptosis was
then quantified by DAPI staining (Figures 2C, S3A and S3B) and
immunoblotting analysis to detect cleaved caspase 3 and PARP
(Figure 2D). We found enhanced 5-FU-induced apoptosis when
caveolin-1 protein expression was knockdown in HT29 cells. In
addition, scrambled and caveolin-1 siRNA-transfected HCT116
cells were treated with a different chemotherapeutic drug,
etoposide. We show enhanced etoposide-induced apoptosis in
HCT116 cells transfected with caveolin-1 siRNA, as compared to
scrambled siRNA-transfected cells, after DAPI staining (Figure 2E)
and immunoblotting analysis to detect activated caspase 3 and
PARP (Figure 2F). In addition, the long-term survival of HCT116
cells after treatment with etoposide was inhibited by knockdown of
caveolin-1 protein expression using siRNA (Figures S4A and S4B).
Ku70 is a Novel Caveolin-1-binding Protein
Caveolin-1 is known to interact with signaling molecules
carrying a caveolin binding domain [14,15]. Ku70 has been
shown to regulate apoptosis [22–25]. Interestingly, Ku70 possesses
a putative caveolin binding domain between amino acids 471 and
478 (Figure 3A). To investigate the molecular mechanism
underlying the caveolin-1-mediated inhibition of apoptosis, we
asked whether Ku70 was a novel caveolin-1-interacting protein.
To this end, we performed pulldown assays using a series of
caveolin-1 deletion mutants fused to GST (Figure 3B). Figures 3C
shows that Ku70 is a novel caveolin-1-binding protein and that the
caveolin scaffolding domain (CSD) of caveolin-1 (residues 82–101)
is sufficient for binding to Ku70.
Figure 2. Caveolin-1 promotes long-term survival and inhibits apoptosis of colon cancer cells after treatment with
chemotherapeutic drugs. HCT116 (A, B, E and F) and HT29 (C and D) colon cancer cells were transfected with siRNA directed against
caveolin-1. Transfection with scrambled siRNA was used as control. One day after transfection, cells were treated with different concentrations of 5-FU
for 48 h (A–D) or etoposide for 24 h (E and F). Untreated cells were used as control. In (A and B), cells were cultured for 7 days and stained with crystal
violet. A crystal violet staining that is representative of three independent experiments is shown in (A), quantification of the number of clones after
crystal violet staining is shown in (B). Values represent mean 6 SEM; *P,0.001; #P,0.005. In (C and E), cells were stained with DAPI and the number
of cells showing nuclear condensation was quantified. Values represent mean 6 SEM; *P,0.001; #P,0.005. In (D and F), cells were subjected to
immunoblotting analysis with antibody probes specific for cleaved caspase 3 and PARP. Immunoblotting with anti-b-actin IgGs was done to show
equal loading.
doi:10.1371/journal.pone.0039379.g002
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The Interaction between Caveolin-1 and Ku70 is Induced
by Chemotherapeutic Drugs and Limits the Release of
Bax from Ku70
Once we demonstrated that Ku70 was a novel caveolin-1-
interacting protein, we then asked whether binding of caveolin-1 to
Ku70 was the molecular mechanism underlying the anti-apoptotic
properties of caveolin-1. HCT116 cells were treated with either 5-
FU or etoposide and the interaction between caveolin-1 and Ku70,
before and after treatment with chemotherapeutic drugs, was
evaluated by coimmunoprecipitation studies. We show in Figure 4A
that the interaction between caveolin-1 and Ku70 was marginal
under resting conditions but dramatically increased upon treatment
with either 5-FU or etoposide. Consistent with these data, Ku70was
mainly localized in the nucleus and, to a lesser extent, diffuse in the
cytoplasm (see arrowheads in Figure 4B) in HCT116 cells under
resting conditions, away from caveolin-1, which was enriched at the
plasma membrane (Figure 4B). In contrast, although nuclear
localization was still evident, Ku70 was found to partially co-
localize with caveolin-1 at the plasma membrane and intracellular
caveolar membranes after 5-FU treatment (see arrows in Figure 4B).
Interestingly, 5-FU, but not etoposide, also stimulated total caveolin-
1 protein expression in HCT116 cells (Figure 4A, lower panel). This
is consistent with the increased caveolin-1 mRNA level induced by
5-FU, but not etoposide, in HCT116 cells (Figure S5A), suggesting
that 5-FU also promotes caveolin-1 protein expression through a
transcriptional-dependent mechanism.
Why does the chemotherapeutic drug-induced interaction
between caveolin-1 and Ku70 act in an anti-apoptotic manner?
Ku70 has been shown to bind to Bax under resting conditions.
Release of Bax from Ku70 and the translocation of Bax to
mitochondria are key steps in the signaling events that link an
apoptotic stimulus to cell death. The molecular mechanisms that
regulate these processes remain to be fully elucidated.Our data show
that caveolin-1 acts as an anti-apoptotic protein (Figures 1 and2) and
chemotherapeutic drugs, which induce apoptosis, promote the
interaction between caveolin-1 and Ku70 (Figures 4A and 4B). To
investigate the functional significance of the binding of caveolin-1 to
Ku70, we tested the hypothesis that binding of caveolin-1 to Ku70
inhibits apoptosis by limiting the release of Bax from Ku70.
HCT116 cells were transfected with either scrambled or caveolin-1
siRNAand treatedwith either 5-FUor etoposide. Protein cell lysates
were then immunoprecipitated with an antibody probe specific for
Bax and immunoprecipitates subjected to immunoblotting analysis
with anti-Ku70 IgGs. Figure 5A shows that both 5-FUand etoposide
stimulated the release of Bax from Ku70 in scrambled siRNA-
transfected cells. Importantly, the dissociation of Bax from Ku70
was potentiated in cells lacking caveolin-1. Thus, the interaction of
caveolin-1 with Ku70 limits the release of Bax from Ku70 induced
by chemotherapeutic drugs. In support of the existence of a caveolin-
1/Ku70/Bax complex after treatment with chemotherapeutic
drugs, we show in Figure 4A that both 5-FU and etoposide
promoted the interaction between caveolin-1 and Bax, and in
Figure 5B that caveolin-1, Ku70 and Bax are all found by
immunoblotting analysis after immunoprecipitation of protein cell
lysates from 5-FU-treated HCT116 cells with antibody probes
specific for either caveolin-1 or Bax.
Knockdown of Caveolin-1 Protein Expression Potentiates
the Chemotherapeutic Drug-induced Conformational
Change of Bax
Activation of Bax is associated with a conformational change
that leads to exposure of the N terminus and can be detected using
the anti-Bax antibody clone 6A7 [29,30]. We show in Figures 5C
and 5D that 6A7 antibody immunoprecipitated Bax only in
HCT116 cells treated with the apoptotic stimulus 5-FU but not in
control cells. Knockdown of caveolin-1 protein expression by
siRNA significantly potentiated binding of the 6A7 antibody to
Bax in cells treated with 5-FU (Figures 5C and 5D). However,
Figure 3. Ku70 binds to the scaffolding domain of caveolin-1. (A) The consensus caveolin binding domain (CBD) is shown together with the
caveolin binding domain of Ku70 (amino acids 471 to 478) and a mutant form of Ku70’s CBD in which aromatic residues were mutated to alanines. (B)
Ponceau S staining of GST alone and GST-caveolin-1 fusion proteins. (C) GST-caveolin-1 fusion protein pull-down assays were performed using cell
lysates from HCT116 cells transiently transfected with wild type Ku70-HA. A blot that is representative of two independent experiments is shown.
doi:10.1371/journal.pone.0039379.g003
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knockdown of caveolin-1 protein expression by itself in untreated
cells failed to promote the conformational change of Bax
(Figures 5C and 5D). Since our results show that chemothera-
peutic drugs stimulate the binding of caveolin-1 with Ku70 and
the interaction of Bax with Ku70 is known to prevent the
activation of Bax, our data suggest that caveolin-1 forms a
complex with Ku70 that inhibits the activation of Bax. The
dissociation of caveolin-1 from Ku70 is not sufficient to activate
Bax but potentiates Bax activation induced by chemotherapeutic
drugs. Consistent with these results, chemotherapeutic drug-
induced translocation of Bax to mitochondria was enhanced in
HCT116 cells in which caveolin-1 protein expression was reduced
by siRNA, as compared to HCT116 cells expressing scrambled
siRNA (Figure 5E). We conclude that binding of caveolin-1 to
Ku70 limits the release of Bax from Ku70 and the activation of
Bax induced by chemotherapeutic drugs.
Enhancement of Apoptosis Induced by the Knockdown
of Caveolin-1 Protein Expression is Dependent upon the
Expression of Bax
If knockdown of caveolin-1 protein expression potentiates
apoptosis in colon cancer cells by enhancing the release of Bax
from Ku70, one would not expect potentiation of apoptosis by
knockdown of caveolin-1 in HCT116 cells lacking Bax expression.
To directly test this possibility, we took advantage of HCT116 Bax
(2/2) null isogenic cells [31], which do not express Bax (data not
shown). Caveolin-1 protein expression was knockdown by siRNA
in HCT116 and HCT116 Bax null cells (Figure 6A). Cells were
then treated with either 5-FU or etoposide and apoptosis was
quantified by DAPI staining. We demonstrate that knockdown of
caveolin-1 protein expression by siRNA potentiated 5-FU-induced
apoptosis in HCT116 cells by 81% but only by 46% in HCT116
Bax null cells (Figure 6B). Similarly, knockdown of caveolin-1
protein expression by siRNA enhanced etoposide-induced apop-
tosis in HCT116 cells by 84% but only by 10% in HCT116 Bax
null cells (Figure 6D). Consistent with these data, the enhanced
activation of caspase 3 by downregulation of caveolin-1 expression
following treatment with either 5-FU or etoposide observed in
HCT116 cells was dramatically inhibited in HCT116 Bax null
cells (Figures 6C and 6E, respectively). Thus, Bax expression plays
a central role in the potentiation of chemotherapeutic drug-
induced apoptosis following knockdown of caveolin-1 in HCT116
cells. The fact that we observed apoptosis after 5-FU treatment
even in HCT116 Bax null cells transfected with scrambled siRNA
(Figures 6B and 6D) suggests that apoptosis in these cells can also
be Bax-independent, confirming previously reported data showing
Bax-independent apoptosis in these cells [32,33]. Finally, the 46%
increase in apoptosis induced by 5-FU found in caveolin-1 siRNA-
Figure 4. Chemotherapeutic drugs promote the Ku70-Cav-1 interaction. (A) HCT116 cells were treated with either etoposide or 5-FU for 24
hours. Untreated cells were used as control. Cell lysates were then immunoprecipitated with an antibody probe specific for caveolin-1 and
immunoprecipitates subjected to immunoblotting analysis with anti-Ku70, anti-Bax and anti-caveolin-1 IgGs. (B) HCT116 colon cancer cells were
transfected with HA-tagged wild type Ku70. One day after transfection, cells were treated with 5-FU for 24 hours. Untreated cells were used as
control. Cells were then subjected to immunofluorescence analysis using antibody probes specific for the HA tag (green) and caveolin-1 (red). Nuclei
were detected by DAPI staining (Blue). Yellow staining in the merged images shows co-localization between caveolin-1 and Ku70 only after 5-FU
treatment (see arrows). Representative images are shown.
doi:10.1371/journal.pone.0039379.g004
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expressing HCT116 Bax null cells, as compared to scrambled
siRNA-expressing HCT116 Bax null cells (Figure 6B), suggests
that, in addition to Bax-dependent apoptosis, caveolin-1 may also
inhibit, to a certain extent, Bax-independent cell death following
treatment with 5-FU.
The Interaction of Ku70 with Caveolin-1 is Required for
the Ku70-dependent Protection against
Chemotherapeutic Drug-induced Apoptosis
Overexpression of Ku70 has been shown to protect against
apoptosis [22,25]. Based on our data showing that binding of
caveolin-1 to Ku70 protects the cells against apoptosis induced by
chemotherapeutic drugs, we would predict less protection against
apoptosis by a mutant form of Ku70 that cannot bind to caveolin-
1. Since we show in Figure 3 that caveolin-1 interacts with Ku70,
to directly test our hypothesis, we generated a mutant form of
Ku70 in which the critical aromatic residues of the caveolin
binding domain of Ku70 were mutated to alanines (WRA-Ku70).
We show that the in vitro binding of WRA-Ku70 to caveolin-1 was
greatly inhibited, as compared to wild type Ku70 (Figures S5B and
S5C). We then overexpressed wild type Ku70 and WRA-Ku70 in
HCT116 cells. Cells were treated with 5-FU and the interaction of
caveolin-1 with Ku70 and Bax was examined by coimmunopre-
cipitation studies. We find that 5-FU promoted the interaction of
caveolin-1 with wild type Ku70 and Bax in cells overexpressing
wild type Ku70 (Figure 7A). In contrast, the interaction of
caveolin-1 with WRA-Ku70 and Bax was only marginally
stimulated by 5-FU treatment in cells overexpressing WRA-
Ku70 (Figure 7A). Consistent with our findings, WRA-Ku70,
similarly to wild type Ku70 (Figure 4B), did not co-localize with
caveolin-1 in HCT116 cells under resting conditions, being mainly
localized in the nucleus and, to a lesser extent, diffuse in the
cytoplasm (see arrowheads in Figure S6). However, in contrast to
wild type Ku70 (Figure 4B), 5-FU failed to promote the co-
Figure 5. Knockdown of caveolin-1 protein expression enhances the dissociation of Bax from Ku70 and the activation of Bax
induced by chemotherapeutic drugs. (A, C, D and E) HCT116 colon cancer cells were transfected with siRNA directed against caveolin-1.
Transfection with scrambled siRNA was used as control. One day after transfection, HCT116 cells were treated with either 5-FU (A, C and D) or
etoposide (A and E) for 24 hours. In (B), untransfected cells were treated with 5-FU for 24 hours. In (A), cell lysates were immunoprecipitated with an
antibody probe specific for Bax and immunoprecipitates subjected to Western blotting analysis with anti-Ku70 and anti-Bax IgGs. In (B), cell lysates
were immunoprecipitated with either anti-caveolin-1 IgGs or anti-Bax IgGs. Immunoprecipitates were then subjected to immunoblotting analysis
with antibody probes specific for caveolin-1, Ku70 and Bax. In (C and D), cell lysates were immunoprecipitated with a Bax (6A7) antibody and
immunoprecipitates subjected to immunoblotting analysis with anti-Bax IgGs. A blot that is representative of three independent experiments is
shown in (C), quantification of Bax levels pulled down by the Bax (6A7) antibody is shown in (D). Values in (D) represent mean 6 SEM; *P,0.001. In
(E), mitochondrial fractions were isolated and expression of Bax in mitochondria was detected by immunoblotting analysis using an antibody probe
specific for Bax.
doi:10.1371/journal.pone.0039379.g005
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localization of WRA-Ku70 with caveolin-1 in HCT116 cells
(Figure S6). Interestingly, overexpression of wild type Ku70, but
not WRA-Ku70, promoted a ,40% decrease in apoptosis
induced by either 5-FU or etoposide (Figures 7B and 7C). In
support to this data, we show in Figure 7D that wild type Ku70, in
contrast to WRA-Ku70, prevented the activation of caspase 3 by
either 5-FU or etoposide and that overexpression of wild type
Ku70, but not WRA-Ku70, limited the Ku70/Bax dissociation
promoted by 5-FU in HCT116 cells (Figure 7E). These results
support our conclusion that the interaction of Ku70 with caveolin-
1 limits the chemotherapeutic drug-induced release of Bax from
Ku70 and therefore Bax-dependent apoptosis.
Discussion
Apoptosis is the process of programmed cell death adopted by
multicellular organisms for proper development and maintenance
of adult individuals. Defective apoptosis has been linked to
pathological conditions. Excessive apoptosis may lead to atrophy
whereas reduced apoptosis may lead to uncontrolled cell
proliferation and cancer. Apoptosis is also a major cytotoxic effect
of chemotherapy. Thus, understanding, at the molecular level,
how apoptosis is regulated will not only bring insight into a
fundamental biological event but also contribute to the develop-
ment of more efficient therapeutic interventions for the treatment
of cancer. 5-fluorouracil is a chemotherapeutic drug that has been
the cornerstone of treatment for patients with colorectal cancer for
almost four decades. 5-FU blocks the enzyme thymidylate synthase
and inhibits both RNA and DNA synthesis. In sensitive cells, 5-FU
induces apoptosis. Unfortunately, tumor responses to 5-FU is
limited by toxicity to tissues containing highly proliferative cell
populations [34]. In this report, we show that knockdown of
caveolin-1 protein expression in colon cancer cells enhances
apoptosis induced by 5-FU and etoposide. Mechanistically, our
data reveal a novel anti-apoptotic mechanism in which the binding
of caveolin-1 to Ku70 limits the dissociation of Bax from Ku70
and the activation of Bax induced by apoptotic stimuli. Consistent
with this conclusion, we show that the enhancement of 5-FU-
Figure 6. Knockdown of caveolin-1 protein expression fails to enhance apoptosis induced by chemotherapeutic drugs in the
absence of Bax expression. HCT116 and HCT116 Bax null cells were transfected with siRNA directed against caveolin-1. Transfection
with scrambled siRNA was used as control. In (A), expression of endogenous caveolin-1 was detected by immunoblotting analysis 48 hours after
transfection using an antibody probe specific for caveolin-1. Immunoblotting with anti-b-actin IgGs was done to show equal loading. In (B–E), 24
hours after transfection, cells were treated with either 5-FU (25 mg/ml) for 48 h (B and C) or etoposide (Etop.; 800 mM) for 24 h (D and E). Untreated
cells were used as control. In (B and D), cells were stained with DAPI and the number of cells showing nuclear condensation was quantified. Values
represent mean 6 SEM; *P,0.001. In (C and E), cells were subjected to immunoblotting analysis with antibody probes specific for cleaved caspase 3.
Immunoblotting with anti-b-actin IgGs was done to show equal loading.
doi:10.1371/journal.pone.0039379.g006
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induced apoptosis after knockdown of caveolin-1 protein expres-
sion is dramatically prevented in the absence of Bax expression.
Therefore, caveolin-1 acts as an anti-apoptotic molecule in colon
cancer cells by inhibiting Bax-dependent cell death.
Overexpression of caveolin-1 was linked to drug-resistance of
cancer cells, including colon cancer cells [35,36]. Our findings
contribute to explain, at the molecular level, the role of caveolin-1
in drug resistance of cancer cells. Increased levels of caveolin-1
may promote resistance to chemotherapeutic drugs by bolstering
the inhibitory action of caveolin-1 on the Ku70-Bax complex. In
fact, in the presence of elevated caveolin-1 levels, the release of
Bax from Ku70 induced by chemotherapeutic drugs would be
further inhibited. This mechanism would also be consistent with a
proposed scenario in which caveolin-1 expression is lost in the
initial phases of cancer development but returns to high levels at
later stages when the tumor has acquired multi-drug resistance
properties (reviewed in [37]).
Caveolin-1 was recently shown to modulate the cellular
response to DNA damage by regulating both homologous
recombination (HR) and non-homologous end joining (NHEJ)
repair pathways [38]. Interestingly, Ku70 was originally discov-
ered as a molecule involved in the repair of DNA double-strand
breaks by non-homologous end joining (NHEJ). Since we
demonstrate in this report that Ku70 is a novel caveolin-1 binding
protein, our findings suggest that caveolin-1 may regulate DNA
repair through modulation of Ku70 functions which are indepen-
dent of apoptosis. How caveolin-1 regulates Ku70 in the context of
DNA repair mechanisms is currently under investigation.
Overexpression of Ku70 has been shown to protect against
apoptosis [22,25]. Our data contribute to explain this previous
finding at the molecular level. We confirmed that overexpression
of wild type Ku70 inhibits both 5-FU- and etoposide-induced
apoptosis of colon cancer cells. More importantly, we show that a
mutant form of Ku70 that cannot interact with caveolin-1 (WRA
Figure 7. WRA Ku70 fails to interact with caveolin-1, to protect against chemotherapeutic drug-induced apoptosis and to limit the
5-FU-induced dissociation of Bax from Ku70. HCT116 cells were transfected with either wild type Ku70-HA (WT Ku70) or WRA Ku70-HA (WRA
Ku70) and treated with different concentrations of either 5-FU (for 24 h in A and E; for 48 h in C and D) or etoposide (for 24 h in C and D). Untreated
cells were used as control. In (A), cell lysates were immunoprecipitated with an antibody probe specific for caveolin-1 and immunoprecipitates
subjected to immunoblotting analysis with anti-HA, anti-Bax and anti-caveolin-1 IgGs. In (B), total expression of WT Ku70-HA and WRA Ku70-HA was
detected by immunoblotting analysis with anti-HA IgGs before drug treatment. In (C), cells were stained with DAPI and the number of cells showing
nuclear condensation was quantified. Values represent mean6 SEM; *P,0.001. In (D), cells were subjected to immunoblotting analysis with antibody
probes specific for cleaved caspase 3. Immunoblotting with anti-b-actin IgGs was done to show equal loading. In (E), cell lysates were
immunoprecipitated with and antibody probe specific for Bax and immunoprecipitates subjected to Western blotting analysis with anti-HA and anti-
Bax IgGs.
doi:10.1371/journal.pone.0039379.g007
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Ku70) fails to inhibit chemotherapeutic drug-induced apoptosis.
Thus, the interaction of Ku70 with caveolin-1 is critical for the
ability of Ku70 to inhibit apotosis. We also found that
overexpression of WRA Ku70, in contrast to wild type Ku70,
fails to inhibit the Bax/Ku70 dissociation after stimulation with
chemotherapeutic drugs, which explains, at the molecular level,
why WRA Ku70 fails to protect against chemotherapeutic drug-
induced apoptosis. Thus, under cellular conditions where Ku70
fails to interact with caveolin-1 (i.e. cells in which caveolin-1
protein expression is knockdown by siRNA or cells expressing the
WRA mutant form of Ku70 that does not interact with caveolin-
1), the ability of Ku70 to limit the release of Bax is prevented.
Together, our data indicate that disruption of the interaction
between caveolin-1 and Ku70 enhances apoptosis and propose the
caveolin-1/Ku70 complex as a novel potential therapeutic target
for the treatment of colon cancer.
Supporting Information
Figure S1 Quantification of nuclear condensation after
knockdown of caveolin-1 protein expression in 5-FU-
treated HCT116 colon cancer cells. HCT116 colon cancer
cells were transfected with siRNA directed against caveolin-1.
Transfection with scrambled siRNA was used as control. One day
after transfection, cells were treated with 5-FU for different periods
of time. Untreated cells were used as control. Cells were then
stained with DAPI. Representative images are shown in (A).
Arrows show examples of cells with nuclear condensation. The
number of cells showing nuclear condensation was quantified in
(B). Values represent mean 6 SEM; *P,0.001.
(TIF)
Figure S2 Knockdown of caveolin-1 protein expression
reduces the number of cells in the S phase of the cell
cycle. HCT116 colon cancer cells were transfected with siRNA
directed against caveolin-1. Transfection with scrambled siRNA
was used as control. One day after transfection, HCT116 cells
were collected, incubated with propidium iodide and subjected to
FACS analysis with the use of a fluorescence-activated cell sorter
(FACStar plus; Becton Dickinson). A representative cell cycle
analysis experiment is shown. Values represent mean from
independent experiments.
(TIF)
Figure S3 Quantification of nuclear condensation after
knockdown of caveolin-1 protein expression in 5-FU-
treated HT29 colon cancer cells. HT29 colon cancer cells
were transfected with siRNA directed against caveolin-1. Trans-
fection with scrambled siRNA was used as control. One day after
transfection, cells were treated with 5-FU for different periods of
time. Untreated cells were used as control. Cells were then stained
with DAPI. Representative images are shown in (A). Arrows show
examples of cells with nuclear condensation. The number of cells
showing nuclear condensation was quantified in (B). Values
represent mean 6 SEM; *P,0.001.
(TIF)
Figure S4 Knockdown of caveolin-1 protein expression
inhibits long-term survival of HCT116 cells after
treatment with etoposide. HCT116 colon cancer cells were
transfected with siRNA directed against caveolin-1. Transfection
with scrambled siRNA was used as control. One day after
transfection, HCT116 cells were treated with different concentra-
tions of etoposide for 1 hour. Untreated cells were used as control.
Cells were then cultured for 7 days and stained with crystal violet.
A representative crystal violet staining after etoposide treatment is
shown in (A). Quantification of crystal violet staining after
etoposide treatment is shown in (B). Values represent mean 6
SEM; *P,0.001; #P,0.005.
(TIF)
Figure S5 5-FU, but not etoposide, increases caveolin-1
mRNA levels in HCT116 cells. The binding of W RA
Ku70 to caveolin-1 is dramatically compromised. (A)
HCT116 cells were treated with either 5-FU or etoposide for 24
hours. Untreated cells were used as control. RNA was extracted
and RT-PCR was performed using primers specific for human
caveolin-1. Amplification of GAPDH was performed by RT-PCR
as an internal control. A representative blot is shown. (B) Ponceau
S staining of GST alone and the GST-caveolin-1 (82–101) fusion
protein. (C) GST-caveolin-1 fusion protein pull-down assays were
performed using cell lysates from HCT116 cells transiently
transfected with either wild type Ku70-HA or WRA Ku70-HA.
A blot that is representative of two independent experiments is
shown.
(TIF)
Figure S6 WRA Ku70 fails to co-localize with caveolin-1
after treatment with 5-FU. HCT116 colon cancer cells were
transfected with HA-tagged WRA Ku70. One day after
transfection, cells were treated with 5-FU for 24 hours. Untreated
cells were used as control. Cells were then subjected to
immunofluorescence analysis using antibody probes specific for
the HA tag (green) and caveolin-1 (red). Nuclei were detected by
DAPI staining (Blue). Representative images are shown.
(TIF)
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